Findings highlight the need for individualized monitoring after discharge, despite low rates of severe toxicities.
|Videos|January 17, 2014
The Changing Landscape of Immunotherapies for the Treatment of Melanoma
Author(s)Harriet Kluger, MD
Harriet Kluger, MD, associate professor of medicine (medical oncology), associate director, Hematology/Oncology Fellowship Program, Yale Cancer Center, comments on the changing landscape of immunotherapies for the treatment of melanoma.
Advertisement
Clinical Pearls
Harriet Kluger, MD, associate professor of medicine (medical oncology), associate director, Hematology/Oncology Fellowship Program, Yale Cancer Center, comments on the changing landscape of immunotherapies for the treatment of melanoma.
- A few years ago, the only immunotherapies approved for the treatment of melanoma were cytokines: interleukin (IL)-2 and interferon
- IL-2 prolongs survival in small subset of patients and interferon has never demonstrated a benefit to survival
- Ipilimumab, approved in 2011, has demonstrated activity in a fair number of patients
- Only 15% of patients treated with ipilimumab achieve an objective response, though an additional subset can see survival benefit
- Inhibitors of PD-1 could be added to ipilimumab for additional benefit
Advertisement
Related to this article
New study shows CT-measured body fat, not BMI, links obesity to higher lung cancer risk via immune T-cell changes—hinting at prevention through weight loss.
Recap the 4 late-breaking phase 3 trials from ESMO 2026 Presidential Symposium I in melanoma, bladder cancer, small cell lung cancer, and prostate cancer.
The phase 2 I-SPY2.2 trial found promising responses with rilvegostomig plus trastuzumab deruxtecan in biomarker-defined, immune-positive tumors.
Adding the mRNA-based individualized neoantigen intismeran to pembrolizumab reduced the risk of disease recurrence or death by 42% in melanoma.
The guidelines incorporate cosibelimab for locally advanced cutaneous squamous cell carcinoma after favorable results in the CK-301-101 trial.
At Rutgers Cancer Institute, neuro-oncologists met to discuss the latest trends in precision brain cancer care with FET-PET imaging, advanced molecular testing, and same-day multidisciplinary clinics.
Advertisement
Advertisement
Trending on Targeted Onc
1
ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care
2
Novel ADCs Show Responses in Ovarian and Cervical Cancer at ESMO 2026
3
ESMO 2026: New Data Advance Prostate, Kidney, and Bladder Cancer Care
4
340B Contract Pharmacy Case Rekindles Scrutiny Over Program Intent
5